author-photo

Brian Fox

Celgene

14

Papers

24

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

2021 International Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Integrative network modeling reveals mechanisms underlying T cell exhaustion

2019 bioRxiv
Show All
- Source
- Cite
- Save
Citations (1)
Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response

2019 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status

2018 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A Novel Immunotherapy: LYC-55716, a Small-molecule RORγ Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma

2018 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

2018 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

2018 Blood
Show All
- Source
- Cite
- Save
Citations (3)